Gapping up
In reaction to strong earnings/guidance: JCP +21.2%, (Nov/Dec comps +3.7%, narrows fourth quarter sales guidance to upper end of range), PKT +21.2%, GBX +9.5%, SONC +7.1%, SVU +3.3%, HALO +2%, MON +1.9%, SIRI +0.9%, SHLM +0.5%
M&A news: PEP +2.3% (3G Capital discusses that 3G Capital may consider targets such as PEP, CPB, K, KRFT , according to reports), CPB +2.1%.
Select oil/gas related names showing strength: SDRL +2.6%, PBR +1.8%, TOT +1.5%, RIG +1.4%, RDS.A +1%, HAL +1%
Other news: FRO +10.1% (still checking), MTW +6.5% (announces Execution of Senior Management Succession Plan) LGF +5.9% (announced the Hunger Games Mockingjay -- Part 1, will be released in China on February 8), ALKS +5.7% (announces positive topline results from the 12-week phase 2 study of ALKS 3831), NDRM +5.4% (cont momentum after yesterdays 8% move higher), WYY +4% (announced that it has received a Task Order under a previously awarded Federal Government Blanket Purchase Agreement), GOL +3.8% (announces a codeshare agreement with Korean Air), GMCR +3.2% (partners with Dr. Pepper (DPS) to sell soda capsules, according to reports), BLUE +3.2% (favorable commentary on Tuesday's Mad Money), TRVN +2.6% (announces the initiation of a Phase 2b clinical trial of TRV130 for acute postoperative pain in patients following abdominoplasty surgery ), TTM +2.5% (rebounding from yday's sell off), ADXS +2.4% (Advaxis and the GOG Foundation to collaborate on global Phase 3 clinical trial of ADXS-HPV in cervical cancer), MTG +2.3% (disclosed it is is implementing changes for bonuses to be paid in 2015 and modified change in control agreements), GPRO +2% (following JP Morgan Tech Forum), OCLS +2% (announces new dermatology division, IntraDerm Pharmaceuticals), GEVA +1.9% (prices 3.0 mln shares of common stock at $94.19 per share), ISIS +1.9% (favorable commentary on Tuesday's Mad Money), UUUU +1.9% (Energy Fuels and Uranerz (URZ) announce conference call and webcast hosted January 8), TWTR +1.8% (moving higher with futures), CERS +1.6% (prices ~12.7 mln share at $5.50/share for expected gross proceeds of $70 mln), INTC +1.3% (presented at CES), CLR +1.2% (following FastMoney mention (Brian Kelly buyer)), RAD +1% (favorable commentary on Tuesday's Mad Money).
Analyst comments: NLST +22.4% (upgraded to Buy at Needham; tgt $1.50), JNS +3.2% (upgraded to Overweight from Underweight at JP Morgan), FSLR +2.8% (upgraded to Neutral from Sell at Goldman), RMTI +1.9% (initiated with an Outperform at Oppenheimer), AXP +1.7% (upgraded to Buy from Neutral at Goldman), MANH +1.6% (upgraded to Strong Buy from Outperform at Raymond James), OUBS +1.3% (upgraded to Overweight at Barclays), AEO +1% (upgraded to Market Perform from Underperform at Cowen)
In reaction to strong earnings/guidance: JCP +21.2%, (Nov/Dec comps +3.7%, narrows fourth quarter sales guidance to upper end of range), PKT +21.2%, GBX +9.5%, SONC +7.1%, SVU +3.3%, HALO +2%, MON +1.9%, SIRI +0.9%, SHLM +0.5%
M&A news: PEP +2.3% (3G Capital discusses that 3G Capital may consider targets such as PEP, CPB, K, KRFT , according to reports), CPB +2.1%.
Select oil/gas related names showing strength: SDRL +2.6%, PBR +1.8%, TOT +1.5%, RIG +1.4%, RDS.A +1%, HAL +1%
Other news: FRO +10.1% (still checking), MTW +6.5% (announces Execution of Senior Management Succession Plan) LGF +5.9% (announced the Hunger Games Mockingjay -- Part 1, will be released in China on February 8), ALKS +5.7% (announces positive topline results from the 12-week phase 2 study of ALKS 3831), NDRM +5.4% (cont momentum after yesterdays 8% move higher), WYY +4% (announced that it has received a Task Order under a previously awarded Federal Government Blanket Purchase Agreement), GOL +3.8% (announces a codeshare agreement with Korean Air), GMCR +3.2% (partners with Dr. Pepper (DPS) to sell soda capsules, according to reports), BLUE +3.2% (favorable commentary on Tuesday's Mad Money), TRVN +2.6% (announces the initiation of a Phase 2b clinical trial of TRV130 for acute postoperative pain in patients following abdominoplasty surgery ), TTM +2.5% (rebounding from yday's sell off), ADXS +2.4% (Advaxis and the GOG Foundation to collaborate on global Phase 3 clinical trial of ADXS-HPV in cervical cancer), MTG +2.3% (disclosed it is is implementing changes for bonuses to be paid in 2015 and modified change in control agreements), GPRO +2% (following JP Morgan Tech Forum), OCLS +2% (announces new dermatology division, IntraDerm Pharmaceuticals), GEVA +1.9% (prices 3.0 mln shares of common stock at $94.19 per share), ISIS +1.9% (favorable commentary on Tuesday's Mad Money), UUUU +1.9% (Energy Fuels and Uranerz (URZ) announce conference call and webcast hosted January 8), TWTR +1.8% (moving higher with futures), CERS +1.6% (prices ~12.7 mln share at $5.50/share for expected gross proceeds of $70 mln), INTC +1.3% (presented at CES), CLR +1.2% (following FastMoney mention (Brian Kelly buyer)), RAD +1% (favorable commentary on Tuesday's Mad Money).
Analyst comments: NLST +22.4% (upgraded to Buy at Needham; tgt $1.50), JNS +3.2% (upgraded to Overweight from Underweight at JP Morgan), FSLR +2.8% (upgraded to Neutral from Sell at Goldman), RMTI +1.9% (initiated with an Outperform at Oppenheimer), AXP +1.7% (upgraded to Buy from Neutral at Goldman), MANH +1.6% (upgraded to Strong Buy from Outperform at Raymond James), OUBS +1.3% (upgraded to Overweight at Barclays), AEO +1% (upgraded to Market Perform from Underperform at Cowen)